Source comparison
MOTS-c Exercise Mimetic Results Timeline: Comparison Across Dosing Protocols
5mg 3×/week (subcutaneous) Glucose disposal improved 10–15% vs baseline Time to exhaustion +12–18% Mitochondrial DNA copy number +28–35% Standard research dosing. Consistent results in metabolically healthy subjects, slower response if insulin-resistant 10mg 3
This comparison does not assign a generated winner or score.
- 5mg 3×/week (subcutaneous)
- Glucose disposal improved 10–15% vs baseline
- Time to exhaustion +12–18%
- Mitochondrial DNA copy number +28–35%
- Standard research dosing. Consistent results in metabolically healthy subjects, slower response if insulin-resistant
- 10mg 3×/week (subcutaneous)
- Glucose disposal improved 18–25% vs baseline
- Time to exhaustion +20–28%
- Mitochondrial DNA copy number +40–48%
- Higher dose accelerates timeline but doesn't change the ceiling. Week 12 outcomes similar to 5mg protocol
- 15mg daily (subcutaneous)
- Glucose disposal improved 22–30% vs baseline
- Time to exhaustion +25–32%
- Mitochondrial DNA copy number +45–52%
- Fastest timeline but higher injection frequency. Best for research models with severe metabolic dysfunction
- 5mg 3×/week + moderate aerobic activity
- Glucose disposal improved 25–32% vs baseline
- Time to exhaustion +30–40%
- Mitochondrial DNA copy number +50–60%
- Synergistic effect. Activity amplifies AMPK signaling beyond what peptide alone triggers